BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250929
DTEND;VALUE=DATE:20251002
DTSTAMP:20260515T044255
CREATED:20250618T133545Z
LAST-MODIFIED:20250724T113321Z
UID:41299-1759104000-1759363199@www.pharmajournalist.com
SUMMARY:6th Genome Editing Therapeutics Summit
DESCRIPTION:With baby KJ successfully receiving the world’s first personalized CRISPR therapy\, alongside continued innovation across in vivo and base editing\, and rapid ex vivo clinical progress\, the genome editing field stands at a pivotal juncture. \nTo mark this definitive CRISPR milestone\, the 6th Genome Editing Therapeutics Summit returns to Boston to celebrate ongoing progress\, whilst also tackling end-to-end challenges from discovery through to commercial strategy. \nUnite with the industry’s leading minds\, as they advance delivery specificity\, spearhead in vivo editing\, ensure precise targeting\, improve translatability\, and build robust clinical strategies to unlock precise\, durable and safe therapeutics. \nThe 2025 Expert Speaker Line-up Includes: \n\nKiran Musunru\, Professor\, Translational Research\, University of Pennsylvania\nTJ Cradick\, Chief Technology Officer\, HuidaGene Therapeutics\nNageswara Kollu\, Senior Director\, Gene Therapy\, Apellis Pharmaceuticals\nAlexandria Petrusich\, Vice President\, Clinical Science\, Prime Medicine\nBradley Ringeisen\, Executive Director\, Innovative Genomics Institute\nChris Brown\, Vice President\, Discovery\, Metagenomi\nAnjulika Chawla\, Vice President\, Medical Affairs\, Clinical Lead\, Bluebird Bio\n\nAlongside 20+ data-driven presentations\, this year’s program will feature a deep-dive workshop dedicated to the impact of baby KJ\, led by Innovative Genomics Institute\, HuidaGene Therapeutics and the University of Pennsylvania. \nEnsure you are part of the most anticipated gene editing event of the year! \nTo know more visit: https://ter.li/rd7cax
URL:http://www.pharmajournalist.com/event/6th-genome-editing-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250929
DTEND;VALUE=DATE:20251002
DTSTAMP:20260515T044255
CREATED:20250701T122415Z
LAST-MODIFIED:20250701T145003Z
UID:41426-1759104000-1759363199@www.pharmajournalist.com
SUMMARY:LEAP TA: Life Sciences
DESCRIPTION:As 2025 shapes up to be a transformative year for talent acquisition in life sciences\, the 7th LEAP TA: Life Sciences returns to Boston\, MA this September (29 – October 1)\, uniting over 120 senior TA professionals from industry pioneers including Pfizer\, AbbVie\, Bristol Myers Squibb\, Bayer\, Edwards Lifesciences\, The Jackson Laboratory\, and more. \nThis is the only event dedicated entirely to helping biopharma reimagine how they attract\, engage\, and retain top talent in an increasingly complex hiring landscape. In a time of political uncertainty\, evolving regulations\, and rapid scientific advancement\, hiring in life sciences has never been more challenging\, or vital to long-term success. \nOver three high-impact days\, uncover how TA leaders are: \n\nNavigating visa challenges\, DEI pushback\, and new workforce expectations\nLeveraging AI\, redefined employer branding\, and technology to build future-ready teams\nDriving value-driven recruitment in the face of political and market disruption\nAdapting to shifting skills requirements through innovative sourcing strategies\n\nFrom small biotechs to global pharma giants\, this event spotlights real-world case studies and actionable insights from across the industry\, all designed to equip you with the tools to compete for niche\, scientific\, and technical talent in today’s market. \nWhether you’re looking to streamline time-to-fill\, reduce turnover\, or build a more resilient and diverse talent pipeline\, LEAP TA: Life Sciences offers a unique opportunity to step back from day-to-day execution\, connect with your peers\, and rethink what’s possible in TA. \nJoin the most forward-thinking talent acquisition leaders in life sciences to shape the future of hiring in 2025 and beyond.
URL:http://www.pharmajournalist.com/event/leap-ta-life-sciences-2025/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="LEAP HR":MAILTO:leaphr@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250929
DTEND;VALUE=DATE:20251002
DTSTAMP:20260515T044255
CREATED:20250717T103452Z
LAST-MODIFIED:20250717T103536Z
UID:41520-1759104000-1759363199@www.pharmajournalist.com
SUMMARY:9th MASH Drug Development Summit
DESCRIPTION:The 9th MASH Drug Development Summit is the definitive meeting for pharma and biotech leaders advancing the next generation of therapies for MASH. With the approval of Rezdiffra signaling a new era\, the race is on to deliver more effective\, patient-centered treatments. \nThis year\, dive into novel mechanisms of action\, non-invasive biomarkers\, and strategic combination and sequential therapies. Hear from experts at Eli Lilly\, Pfizer\, Takeda\, Madrigal\, Akero\, 89 Bio\, and more as they share cutting-edge research and clinical strategies targeting diverse patient populations. \nJoin 60+ MASH scientists and drug developers\, gain critical insights\, and build meaningful collaborations over 10+ hours of dedicated networking. Don’t miss the Pre-Conference Combination & Sequential Therapy Day for a focused deep dive into emerging treatment approaches. \nFind out more now: https://ter.li/d9r0pm
URL:http://www.pharmajournalist.com/event/9th-mash-drug-development-summit/
LOCATION:Hyatt Regency Boston / Cambridge\, 575 Memorial Dr\, Cambridge\, MA\, 02139\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251007
DTEND;VALUE=DATE:20251010
DTSTAMP:20260515T044255
CREATED:20250624T110339Z
LAST-MODIFIED:20250624T110339Z
UID:41387-1759795200-1760054399@www.pharmajournalist.com
SUMMARY:2nd Raw Materials for Cell & Gene Therapy Summit
DESCRIPTION:Unlock the future of cell and gene therapy manufacturing at the 2nd Raw Materials for Cell & Gene Therapy Summit. This is your exclusive opportunity to hear directly from regulatory and standards leaders such as Andrew Sarafanov (FDA) and Rebecca Potts (USP)\, as they share the latest thinking on BLA review expectations\, raw material characterization\, and the evolving global standards landscape. \nWith the cell and gene therapy industry facing increasing complexity and supply chain uncertainty\, top innovators from Vertex\, Genentech\, and Bristol Myers Squibb will reveal how they’re reengineering supplier strategies\, through dual sourcing\, co-development\, and rigorous vendor qualification. \nFind out more: https://ter.li/yesw2g \nExplore real-world solutions to qualification challenges and variability risks with insights from Ultragenyx\, Abeona Therapeutics\, and Metagenomi. Through hands-on workshops\, strategic roundtables\, and high-impact networking\, you’ll walk away with the connections and frameworks needed to strengthen your quality programs and stay ahead of regulatory expectations. The time to align\, adapt\, and advance is now.
URL:http://www.pharmajournalist.com/event/2nd-raw-materials-for-cell-gene-therapy-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251021
DTEND;VALUE=DATE:20251024
DTSTAMP:20260515T044255
CREATED:20250620T105534Z
LAST-MODIFIED:20250620T105629Z
UID:41341-1761004800-1761263999@www.pharmajournalist.com
SUMMARY:7th Gene Therapy Analytical Development Summit
DESCRIPTION:Driving Analytical Excellence from Pre-IND Through BLA for Next-Generation Gene Therapies \nReturning to Boston this October\, the 7th Gene Therapy Analytical Development Summit is the industry’s definitive meeting for advancing assay development and analytical strategy across the gene therapy lifecycle. As gene therapy platforms expand beyond AAV to encompass mRNA\, CRISPR-based modalities\, LNPs\, and novel capsids\, analytical teams must evolve in parallel to meet growing regulatory scrutiny and technical complexity. \nThis summit brings together analytical development\, QC\, and regulatory experts to share practical insights on validating potency assays\, genome integrity\, and advanced characterization tools to ensure product consistency\, safety\, and regulatory readiness from early development through to BLA and commercial launch. \nWith expert contributions from leaders at Beam Therapeutics\, Sarepta\, Astellas\, Spark Therapeutics\, Adverum\, REGENXBIO\, and GenSight Biologics\, attendees will explore real-world solutions to persistent challenges in full or empty capsid quantification\, aggregation profiling\, stability assay design\, and assay transfer into GMP environments. \nFeatured speakers include Johnson Varghese\, Vice President of Analytical Sciences at Beam Therapeutics\, sharing phase-appropriate validation strategies\, and Sue Duan\, Head of Analytical Development at Astellas\, who will discuss genome integrity testing across multiple vector platforms. Also presenting are Uditha DeAlwis of Sarepta Therapeutics and Vanessa Strings-Ufombah from Adverum Biotechnologies\, offering unique perspectives on aligning assay strategies with global regulatory expectations. \nAttendees will gain exposure to cutting-edge techniques including long-read sequencing\, digital PCR\, analytical ultracentrifugation\, and mass photometry\, with a focus on integrating these tools into QC-ready workflows that meet IND\, BLA\, and RMAT requirements. \nWith two technical tracks\, this event delivers unmatched depth across bioassays\, molecular analytics\, and physicochemical characterization\, empowering you to optimize existing platforms or develop robust analytics for new therapeutic modalities. \nWhether refining potency assays\, reducing batch variability\, or preparing for regulatory submission\, this is your opportunity to benchmark with peers and shape the future of gene therapy analytics in 2025 and beyond. \nDownload the Brochure Here for More Information: https://ter.li/wld1o2
URL:http://www.pharmajournalist.com/event/7th-gene-therapy-analytical-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251022
DTEND;VALUE=DATE:20251024
DTSTAMP:20260515T044255
CREATED:20250731T101641Z
LAST-MODIFIED:20250731T101641Z
UID:41595-1761091200-1761263999@www.pharmajournalist.com
SUMMARY:3rd Spatial Biology for Drug Development Summit
DESCRIPTION:The 3rd Spatial Biology for Drug Development Summit is your opportunity to come together with leading biopharma experts to address these challenges within the spatial biology space head-on. \n \nAcross an intensive 2-day agenda\, you’ll explore practical solutions to issues spanning data infrastructure\, multi-omics integration\, standardization\, scalability\, and translation into the clinic. This year’s forum will equip you with the latest data-driven strategies to not only overcome obstacles but to maximize the value of spatial biology for deeper disease insights\, robust target identification\, biomarker discovery\, and more. \nFind out more here: https://ter.li/otrpyk \nSpatial biology is at a turning point. Rapid advances in resolution\, sensitivity\, and multi-omics integration are delivering more robust and clinically meaningful insights than ever before. Recent collaborations and investments\, such as GSK’s partnership with Relation Therapeutics and Sanofi’s expanded partnership with Owkin\, highlight the strong momentum and confidence building across the sector. Yet\, challenges around data standardization\, integration\, scalability\, and cost continue to limit widespread adoption\, particularly among small and mid-sized biopharma companies. \nNo other meeting will give you the chance to connect with 70+ spatial biology experts for *free and take away fresh\, actionable data from AstraZeneca\, Takeda\, AbbVie\, Genentech\, Amgen\, Pfizer\, Johnson & Johnson\, and many more – the exact people you need to meet to move your work forward. \nJoin the spatial biology community (for free) here: https://ter.li/fvnrcc
URL:http://www.pharmajournalist.com/event/3rd-spatial-biology-for-drug-development-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251027
DTEND;VALUE=DATE:20251030
DTSTAMP:20260515T044255
CREATED:20250604T112925Z
LAST-MODIFIED:20250805T122256Z
UID:41188-1761523200-1761782399@www.pharmajournalist.com
SUMMARY:13th IMPACCT Real-World Evidence Summit
DESCRIPTION:With CMS introducing new guidance for RWD studies\, the FDA announcing a new RWE Center\, and RWD becoming more accessible\, it is clear that RWE will play an increasingly pivotal role in the drug development lifecycle. But uncertainties still remain for the experts applying RWE. \nReturning to Boston\, the 13th IMPACCT Real-World Evidence Summit is the only industry-focused meeting dedicated to uniting RWE experts to consolidate and optimize their RWE strategies. Join 140+ industry pioneers from top pharma and biotech companies\, as they share real-world case studies\, the latest industry insights\, and transformative strategies to upskill your team with the knowledge to advance your RWE utility. \nFind out more \nWhat Can You Expect? \n\nHear how Pfizer are using AI to refine data quality through optimized data generation\, data pipeline automation\, and data augmentation.\nIdentify key tokenization methods to ensure consistency\, interoperability\, and improved data utility for regulatory and payer decision making with AstraZeneca.\nLearn how Abbvie are empowering their value and evidence teams with timely insights to support market access and strategic planning.\nBuild a centralized evidence strategy that aligns your cross-functional teams and ensures consistent objectives with Otsuka and Ionis Pharmaceuticals.\n\nDiscover the extensive list of sessions\, speakers and case studies in our agenda! \nSeize your opportunity to gain invaluable industry insights\, address challenges and foster connections\, to perfect your data-quality and enhance your RWE approaches.
URL:http://www.pharmajournalist.com/event/13th-impacct-real-world-evidence-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251027
DTEND;VALUE=DATE:20251031
DTSTAMP:20260515T044255
CREATED:20250613T093335Z
LAST-MODIFIED:20250613T102703Z
UID:41269-1761523200-1761868799@www.pharmajournalist.com
SUMMARY:8th TPD & Induced Proximity Summit
DESCRIPTION: Returning as the industry’s definitive forum from early discovery to clinical development\, the 8th Annual TPD & Induced Proximity Summit is the world’s largest and longest-standing forum for proximity-based modalities\, enabling you to fully immerse yourself in the breadth and depth of cutting-edge induced proximity therapeutic development. \nFeaturing key leaders such as Arvinas\, Nurix Therapeutics\, C4 Therapeutics\, and innovative newcomers including Larkspur Bio\, Magnet Biomedicine\, TrimTech Therapeutics\, as well as the co-founders of TPD\, Craig Crews and Ray Deshaies\, this is your ultimate meeting to hear the latest clinical data\, forge strategic relationships\, and capitalize on the huge opportunity for this modality to treat patients with high unmet clinical need. \nDownload the event guide for full details: https://ter.li/i9k5iz
URL:http://www.pharmajournalist.com/event/8th-tpd-induced-proximity-summit/
LOCATION:The Westin Boston Seaport District\, 425 Summer Street\, Boston\, MA\, 02210\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR